{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:40:47Z","timestamp":1786995647774,"version":"build-2736575974"},"reference-count":127,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T00:00:00Z","timestamp":1712448000000},"content-version":"am","delay-in-days":342,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100018693","name":"H2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["BT\/IN\/EU-INF\/17\/GK\/19-20"],"award-info":[{"award-number":["BT\/IN\/EU-INF\/17\/GK\/19-20"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-19-CE17-0021-BASIN"],"award-info":[{"award-number":["ANR-19-CE17-0021-BASIN"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.pharmthera.2023.108399","type":"journal-article","created":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T20:59:19Z","timestamp":1680123559000},"page":"108399","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["The implication of anti-PD-1 therapy in cancer patients for the vaccination against viral and other infectious diseases"],"prefix":"10.1016","volume":"245","author":[{"given":"Sruthi Vijaya","family":"Retnakumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Chauvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagadeesh","family":"Bayry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.pharmthera.2023.108399_bb0005","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1080\/21645515.2015.1062189","article-title":"Practical review of immunizations in adult patients with cancer","volume":"11","author":"Ariza-Heredia","year":"2015","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"7","key":"10.1016\/j.pharmthera.2023.108399_bb0010","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.3390\/cancers11071037","article-title":"AP-1 transcription factors as regulators of immune responses in Cancer","volume":"11","author":"Atsaves","year":"2019","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.pharmthera.2023.108399_bb0015","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1038\/s41591-021-01387-6","article-title":"Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2","volume":"27","author":"Au","year":"2021","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2023.108399_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111957","article-title":"Potential protective role of the anti-PD-1 blockade against SARS-CoV-2 infection","volume":"142","author":"Awadasseid","year":"2021","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"7077","key":"10.1016\/j.pharmthera.2023.108399_bb0025","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection","volume":"439","author":"Barber","year":"2006","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.pharmthera.2023.108399_bb0030","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.annonc.2020.03.290","article-title":"Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD-1 or PD-L1","volume":"31","author":"Bayle","year":"2020","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology"},{"issue":"14","key":"10.1016\/j.pharmthera.2023.108399_bb0035","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.2217\/imt-2018-0080","article-title":"INfluenza vaccine indication during therapy with immune checkpoint inhibitors: A transversal challenge. The INVIDIa study","volume":"10","author":"Bersanelli","year":"2018","journal-title":"Immunotherapy"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108399_bb0040","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002619","article-title":"INfluenza vaccine indication during therapy with immune checkpoint inhibitors: A multicenter prospective observational study (INVIDIa-2)","volume":"9","author":"Bersanelli","year":"2021","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1016\/j.pharmthera.2023.108399_bb0045","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.838448","article-title":"SARS-CoV-2 induces cytokine responses in human basophils","volume":"13","author":"Bonam","year":"2022","journal-title":"Frontiers in Immunology"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108399_bb0050","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3390\/cells11050801","article-title":"IFN-\u03b3 induces PD-L1 expression in primed human basophils","volume":"11","author":"Bonam","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.pharmthera.2023.108399_bb0465","doi-asserted-by":"crossref","first-page":"985","DOI":"10.2217\/fmb-2022-0103","article-title":"Role of the PD-1 and PD-L1 axis in COVID-19","volume":"17","author":"Bonam","year":"2022","journal-title":"Future Microbiology"},{"key":"10.1016\/j.pharmthera.2023.108399_bb0055","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3389\/fimmu.2019.00168","article-title":"Cold tumors: A therapeutic challenge for immunotherapy","volume":"10","author":"Bonaventura","year":"2019","journal-title":"Frontiers in Immunology"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108399_bb0060","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.immuni.2016.04.023","article-title":"Targeting T cell co-receptors for Cancer therapy","volume":"44","author":"Callahan","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2023.108399_bb0065","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ejca.2021.08.035","article-title":"COVID-19 vaccines in adult cancer patients with solid tumours undergoing active treatment: Seropositivity and safety. A prospective observational study in Italy","volume":"157","author":"Cavanna","year":"2021","journal-title":"European Journal of Cancer (Oxford, England: 1990)"},{"key":"10.1016\/j.pharmthera.2023.108399_bb0070","article-title":"Response efficacy of PD-1 and PD-L1 inhibitors in clinical trials: A systematic review and Meta-analysis","volume":"11","author":"Chen","year":"2021","journal-title":"Frontiers in Oncology"},{"issue":"15_suppl","key":"10.1016\/j.pharmthera.2023.108399_bb0075","doi-asserted-by":"crossref","first-page":"e15073","DOI":"10.1200\/JCO.2018.36.15_suppl.e15073","article-title":"Safety of influenza vaccination in patients undergoing immunotherapy treatment for advanced cancer","volume":"36","author":"Chong","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108399_bb0080","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/cid\/ciz202","article-title":"Safety of inactivated influenza vaccine in Cancer patients receiving immune checkpoint inhibitors","volume":"70","author":"Chong","year":"2020","journal-title":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America"},{"issue":"9","key":"10.1016\/j.pharmthera.2023.108399_bb0085","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1038\/mt.2012.98","article-title":"PD-1\/PD-L1 blockade can enhance HIV-1 gag-specific T cell immunity elicited by dendritic cell-directed lentiviral vaccines","volume":"20","author":"Dai","year":"2012","journal-title":"Molecular Therapy: The Journal of the American Society of Gene Therapy"},{"issue":"24","key":"10.1016\/j.pharmthera.2023.108399_bb0090","doi-asserted-by":"crossref","first-page":"6815","DOI":"10.1158\/1078-0432.CCR-21-2439","article-title":"Immunogenicity and safety of COVID-19 vaccine BNT162b2 for patients with solid cancer: A large cohort prospective study from a single institution","volume":"27","author":"Di Noia","year":"2021","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108399_bb0095","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.3390\/ijms23052847","article-title":"Challenges of the immunotherapy: Perspectives and limitations of the immune checkpoint inhibitor treatment","volume":"23","author":"Dobosz","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2023.108399_bb0100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.715234","article-title":"CD8+ T cell exhaustion in Cancer","volume":"12","author":"Dolina","year":"2021","journal-title":"Frontiers in Immunology"},{"issue":"12","key":"10.1016\/j.pharmthera.2023.108399_bb0105","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/70932","article-title":"B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nature Medicine"},{"issue":"7","key":"10.1016\/j.pharmthera.2023.108399_bb0110","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.trecan.2020.02.022","article-title":"Turning cold into hot: Firing up the tumor microenvironment","volume":"6","author":"Duan","year":"2020","journal-title":"Trends in Cancer"},{"issue":"12","key":"10.1016\/j.pharmthera.2023.108399_bb0115","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s00262-016-1906-6","article-title":"Anti-PD-1 inhibits Foxp3+ Treg cell conversion and unleashes intratumoural effector T cells thereby enhancing the efficacy of a cancer vaccine in a mouse model","volume":"65","author":"Dyck","year":"2016","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"12_Supplement","key":"10.1016\/j.pharmthera.2023.108399_bb0120","doi-asserted-by":"crossref","first-page":"5208","DOI":"10.1158\/1538-7445.AM2022-5208","article-title":"Abstract 5208: Circulating T cell: B cell: NK cell axis associated with response to pembrolizumab plus doxorubicin in patients with metastatic triple negative breast cancer","volume":"82","author":"Egelston","year":"2022","journal-title":"Cancer Research"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108399_bb0125","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1016\/j.jid.2021.02.548","article-title":"522 associations between influenza vaccine and immunotherapy outcomes in metastatic melanoma patients","volume":"141","author":"Erickson","year":"2021","journal-title":"Journal of Investigative Dermatology"},{"issue":"7","key":"10.1016\/j.pharmthera.2023.108399_bb0130","doi-asserted-by":"crossref","first-page":"e573","DOI":"10.1200\/JOP.19.00495","article-title":"Safety of influenza vaccine in patients with Cancer receiving Pembrolizumab","volume":"16","author":"Failing","year":"2020","journal-title":"JCO Oncology Practice"},{"issue":"12","key":"10.1016\/j.pharmthera.2023.108399_bb0135","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s43018-021-00274-w","article-title":"Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study","volume":"2","author":"Fendler","year":"2021","journal-title":"Nature Cancer"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108399_bb0140","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ccell.2021.12.013","article-title":"Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer","volume":"40","author":"Fendler","year":"2022","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.pharmthera.2023.108399_bb0145","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ccell.2022.03.010","article-title":"Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer","volume":"40","author":"Fendler","year":"2022","journal-title":"Cancer Cell"},{"issue":"10328","key":"10.1016\/j.pharmthera.2023.108399_bb0150","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(22)00147-7","article-title":"Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer","volume":"399","author":"Fendler","year":"2022","journal-title":"Lancet (London, England)"},{"issue":"4","key":"10.1016\/j.pharmthera.2023.108399_bb0155","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1001\/jamaoncol.2021.7777","article-title":"SARS-CoV-2 antibody response to 2 or 3 doses of the BNT162b2 vaccine in patients treated with anticancer agents","volume":"8","author":"Fenioux","year":"2022","journal-title":"JAMA Oncology"},{"issue":"24","key":"10.1016\/j.pharmthera.2023.108399_bb0160","doi-asserted-by":"crossref","first-page":"6273","DOI":"10.1158\/0008-5472.CAN-21-3554","article-title":"Longitudinal SARS-CoV-2 mRNA vaccine-induced humoral immune responses in patients with Cancer","volume":"81","author":"Figueiredo","year":"2021","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2023.108399_bb0165","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ejca.2021.05.036","article-title":"High levels of anti-SARS-CoV-2 IgG antibodies in previously infected patients with cancer after a single dose of BNT 162b2 vaccine","volume":"154","author":"Fong","year":"2021","journal-title":"European Journal of Cancer (Oxford, England: 1990)"},{"issue":"13","key":"10.1016\/j.pharmthera.2023.108399_bb0170","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"The Journal of Experimental Medicine"},{"issue":"7","key":"10.1016\/j.pharmthera.2023.108399_bb0175","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the Pd-1 Immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"Journal of Experimental Medicine"},{"issue":"11","key":"10.1016\/j.pharmthera.2023.108399_bb0180","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/intimm\/dxx039","article-title":"IVIG-mediated effector functions in autoimmune and inflammatory diseases","volume":"29","author":"Galeotti","year":"2017","journal-title":"International Immunology"},{"issue":"9","key":"10.1016\/j.pharmthera.2023.108399_bb0185","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1084\/jem.187.9.1383","article-title":"Induction and exhaustion of lymphocytic choriomeningitis virus\u2013specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I\u2013peptide complexes","volume":"187","author":"Gallimore","year":"1998","journal-title":"Journal of Experimental Medicine"},{"key":"10.1016\/j.pharmthera.2023.108399_bb0190","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.3389\/fimmu.2018.01637","article-title":"T follicular helper cells in autoimmune disorders","volume":"9","author":"Gensous","year":"2018","journal-title":"Frontiers in Immunology"},{"issue":"9","key":"10.1016\/j.pharmthera.2023.108399_bb0195","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.7150\/jca.57334","article-title":"A snapshot of the PD-1\/PD-L1 pathway","volume":"12","author":"Ghosh","year":"2021","journal-title":"Journal of Cancer"},{"issue":"15_suppl","key":"10.1016\/j.pharmthera.2023.108399_bb0200","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1200\/JCO.2018.36.15_suppl.3053","article-title":"Impact of the influenza vaccination on cancer patients undergoing therapy with immune checkpoint inhibitors (ICI)","volume":"36","author":"Gopalakrishnan","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1016\/j.pharmthera.2023.108399_bb0205","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1001\/jamaoncol.2021.2675","article-title":"Serologic status and toxic effects of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing treatment for Cancer","volume":"7","author":"Goshen-Lago","year":"2021","journal-title":"JAMA Oncology"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108399_bb0210","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jtho.2021.10.015","article-title":"Efficacy of severe acute respiratory syndrome Coronavirus-2 vaccine in patients with thoracic cancer: A prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses","volume":"17","author":"Gounant","year":"2022","journal-title":"Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer"},{"key":"10.1016\/j.pharmthera.2023.108399_bb0215","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.935806","article-title":"PD-L1 up-regulation in prostate cancer cells by Porphyromonas gingivalis","volume":"12","author":"Groeger","year":"2022","journal-title":"Frontiers in Cellular and Infection Microbiology"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108399_bb0220","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1177\/1078155219868758","article-title":"Immune-mediated adverse events following influenza vaccine in cancer patients receiving immune checkpoint inhibitors","volume":"26","author":"Gwynn","year":"2020","journal-title":"Journal of Oncology Pharmacy Practice: Official Publication of the International Society of Oncology Pharmacy Practitioners"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108399_bb0225","first-page":"727","article-title":"PD-1\/PD-L1 pathway: Current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"American Journal of Cancer Research"},{"issue":"7930","key":"10.1016\/j.pharmthera.2023.108399_bb0230","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41586-022-05257-0","article-title":"PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program","volume":"610","author":"Hashimoto","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2023.108399_bb0235","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1146\/annurev-med-012017-043208","article-title":"CD8 T cell exhaustion in chronic infection and Cancer: Opportunities for interventions","volume":"69","author":"Hashimoto","year":"2018","journal-title":"Annual Review of Medicine"},{"issue":"8","key":"10.1016\/j.pharmthera.2023.108399_bb0240","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/s41590-022-01274-3","article-title":"PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine","volume":"23","author":"Herati","year":"2022","journal-title":"Nature Immunology"},{"issue":"11","key":"10.1016\/j.pharmthera.2023.108399_bb0245","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.2217\/fon-2020-0967","article-title":"Addressing resistance to immune checkpoint inhibitor therapy: An urgent unmet need","volume":"17","author":"Hu-Lieskovan","year":"2021","journal-title":"Future Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108399_bb0250","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/ced.14852","article-title":"Severe cutaneous adverse reaction following COVID-19 vaccination and immunotherapy: A second hit?","volume":"47","author":"Hussain","year":"2022","journal-title":"Clinical and Experimental Dermatology"},{"key":"10.1016\/j.pharmthera.2023.108399_bb0255","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.875974","article-title":"Overview of checkpoint inhibitors mechanism of action: Role of immune-related adverse events and their treatment on progression of underlying Cancer","volume":"9","author":"Iranzo","year":"2022","journal-title":"Frontiers in Medicine"},{"issue":"11","key":"10.1016\/j.pharmthera.2023.108399_bb0260","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"The EMBO Journal"},{"issue":"6","key":"10.1016\/j.pharmthera.2023.108399_bb0265","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1158\/1078-0432.CCR-14-1429","article-title":"Translational implications of tumor heterogeneity","volume":"21","author":"Jamal-Hanjani","year":"2015","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108399_bb0270","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2023.108399_bb0275","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3389\/fimmu.2020.00487","article-title":"The role of PD-1 in acute and chronic infection","volume":"11","author":"Jubel","year":"2020","journal-title":"Frontiers in Immunology"},{"issue":"20","key":"10.1016\/j.pharmthera.2023.108399_bb0280","doi-asserted-by":"crossref","first-page":"9999","DOI":"10.1073\/pnas.1822001116","article-title":"PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer","volume":"116","author":"Kamada","year":"2019","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"15_suppl","key":"10.1016\/j.pharmthera.2023.108399_bb0285","doi-asserted-by":"crossref","first-page":"e14607","DOI":"10.1200\/JCO.2017.35.15_suppl.e14607","article-title":"Safety and efficacy of concurrent administration of influenza vaccine in patients undergoing anti-PD-1 immunotherapy","volume":"35","author":"Kanaloupitis","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1016\/j.pharmthera.2023.108399_bb0290","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1093\/infdis\/jiaa291","article-title":"Cell-mediated immunogenicity of influenza vaccination in patients with Cancer receiving immune checkpoint inhibitors","volume":"222","author":"Kang","year":"2020","journal-title":"The Journal of Infectious Diseases"},{"issue":"33","key":"10.1016\/j.pharmthera.2023.108399_bb0295","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.2217\/fon-2021-0597","article-title":"Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy","volume":"17","author":"Karacin","year":"2021","journal-title":"Future Oncology (London, England)"},{"issue":"6","key":"10.1016\/j.pharmthera.2023.108399_bb0300","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02824-21","article-title":"Wnt-\u03b2-catenin signaling in human dendritic cells mediates regulatory T-cell responses to fungi via the PD-L1 pathway","volume":"12","author":"Karnam","year":"2021","journal-title":"MBio"},{"issue":"55","key":"10.1016\/j.pharmthera.2023.108399_bb0305","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abf3861","article-title":"PD-1 blockade exacerbates Mycobacterium tuberculosis infection in rhesus macaques","volume":"6","author":"Kauffman","year":"2021","journal-title":"Science Immunology"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108399_bb0310","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/cid\/ciz1092","article-title":"Immunogenicity of influenza vaccination in patients with Cancer receiving immune checkpoint inhibitors","volume":"71","author":"Keam","year":"2020","journal-title":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America"},{"issue":"7764","key":"10.1016\/j.pharmthera.2023.108399_bb0315","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","article-title":"TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion","volume":"571","author":"Khan","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108399_bb0320","doi-asserted-by":"crossref","first-page":"e738","DOI":"10.1097\/CAD.0000000000001162","article-title":"Intravenous immunoglobulin efficacy on pembrolizumab induced severe toxic epidermal necrolysis","volume":"33","author":"Kian","year":"2022","journal-title":"Anti-Cancer Drugs"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108399_bb0325","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02121-20","article-title":"A combination of anti-PD-L1 treatment and therapeutic vaccination facilitates improved retroviral clearance via reactivation of highly exhausted T cells","volume":"12","author":"Knuschke","year":"2021","journal-title":"MBio"},{"issue":"4","key":"10.1016\/j.pharmthera.2023.108399_bb0330","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.celrep.2016.09.068","article-title":"Non-oncogenic acute viral infections disrupt anti-cancer responses and Lead to accelerated cancer-specific host death","volume":"17","author":"Kohlhapp","year":"2016","journal-title":"Cell Reports"},{"issue":"11","key":"10.1016\/j.pharmthera.2023.108399_bb0335","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/s41590-020-0769-3","article-title":"The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies","volume":"21","author":"Kumagai","year":"2020","journal-title":"Nature Immunology"},{"key":"10.1016\/j.pharmthera.2023.108399_bb0340","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.semcancer.2021.05.022","article-title":"The depths of PD-1 function within the tumor microenvironment beyond CD8+ T cells","volume":"86","author":"Laba","year":"2022","journal-title":"Seminars in Cancer Biology"},{"issue":"12","key":"10.1016\/j.pharmthera.2023.108399_bb0345","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2217\/imt-2021-0342","article-title":"Development of hepatitis triggered by SARS-CoV-2 vaccination in patient with cancer during immunotherapy: A case report","volume":"14","author":"Lasagna","year":"2022","journal-title":"Immunotherapy"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108399_bb0350","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nature Immunology"},{"issue":"29","key":"10.1016\/j.pharmthera.2023.108399_bb0355","doi-asserted-by":"crossref","first-page":"10691","DOI":"10.1073\/pnas.0307252101","article-title":"PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells","volume":"101","author":"Latchman","year":"2004","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108399_bb0360","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40425-018-0353-7","article-title":"Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events","volume":"6","author":"L\u00e4ubli","year":"2018","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108399_bb0365","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1128\/IAI.02621-14","article-title":"PD-1 deficiency enhances humoral immunity of malaria infection treatment vaccine","volume":"83","author":"Liu","year":"2015","journal-title":"Infection and Immunity"},{"issue":"8","key":"10.1016\/j.pharmthera.2023.108399_bb0370","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3390\/vaccines10081195","article-title":"Safety and efficacy of influenza vaccination in patients receiving immune checkpoint inhibitors. Systematic review with meta-analysis","volume":"10","author":"Lopez-Olivo","year":"2022","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108399_bb0375","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1001\/jamaoncol.2021.5437","article-title":"Humoral immune response in Hematooncological patients and health care workers who received SARS-CoV-2 vaccinations","volume":"8","author":"Mair","year":"2022","journal-title":"JAMA Oncology"},{"key":"10.1016\/j.pharmthera.2023.108399_bb0380","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ejca.2022.01.019","article-title":"Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: Immune responses and adverse events - a retrospective cohort study","volume":"165","author":"Mair","year":"2022","journal-title":"European Journal of Cancer (Oxford, England: 1990)"},{"issue":"8","key":"10.1016\/j.pharmthera.2023.108399_bb0385","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1001\/jamaoncol.2021.2155","article-title":"Evaluation of Seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer","volume":"7","author":"Massarweh","year":"2021","journal-title":"JAMA Oncology"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108399_bb0390","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.4049\/jimmunol.1401673","article-title":"PD-1 suppresses protective immunity to Streptococcus pneumoniae through a B cell-intrinsic mechanism","volume":"194","author":"McKay","year":"2015","journal-title":"Journal of Immunology (Baltimore, Md.: 1950)"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108399_bb0395","doi-asserted-by":"crossref","first-page":"11638","DOI":"10.1038\/s41598-019-48225-x","article-title":"PD-1 of Sigmodon hispidus: Gene identification, characterization and preliminary evaluation of expression in inactivated RSV vaccine-induced enhanced respiratory disease","volume":"9","author":"Muralidharan","year":"2019","journal-title":"Scientific Reports"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108399_bb0400","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1073\/pnas.1904022116","article-title":"Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer","volume":"117","author":"Newman","year":"2020","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"10","key":"10.1016\/j.pharmthera.2023.108399_bb0405","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1093\/intimm\/10.10.1563","article-title":"Immunological studies on PD-1 deficient mice: Implication of PD-1 as a negative regulator for B cell responses","volume":"10","author":"Nishimura","year":"1998","journal-title":"International Immunology"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108399_bb0410","doi-asserted-by":"crossref","DOI":"10.1111\/1346-8138.16304","article-title":"Fulminant type 1 diabetes mellitus triggered by coronavirus disease 2019 vaccination in an advanced melanoma patient given adjuvant nivolumab therapy. The","volume":"49","author":"Ohuchi","year":"2022","journal-title":"Journal of Dermatology"},{"issue":"7","key":"10.1016\/j.pharmthera.2023.108399_bb0415","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/S1470-2045(22)00203-0","article-title":"Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours","volume":"23","author":"Oosting","year":"2022","journal-title":"The Lancet. Oncology"},{"issue":"12","key":"10.1016\/j.pharmthera.2023.108399_bb0420","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/S1470-2045(21)00574-X","article-title":"mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: A prospective, multicentre, non-inferiority trial","volume":"22","author":"Oosting","year":"2021","journal-title":"The Lancet Oncology"},{"issue":"8","key":"10.1016\/j.pharmthera.2023.108399_bb0425","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.annonc.2021.04.020","article-title":"Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients","volume":"32","author":"Palich","year":"2021","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology"},{"issue":"10","key":"10.1016\/j.pharmthera.2023.108399_bb0430","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.annonc.2021.06.018","article-title":"High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancers","volume":"32","author":"Palich","year":"2021","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology"},{"key":"10.1016\/j.pharmthera.2023.108399_bb0435","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.3389\/fimmu.2018.02415","article-title":"Immune protection of SIV challenge by PD-1 blockade during vaccination in Rhesus monkeys","volume":"9","author":"Pan","year":"2018","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108399_bb0440","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.03224-20","article-title":"Development of DNA vaccine targeting E6 and E7 proteins of human papillomavirus 16 (HPV16) and HPV18 for immunotherapy in combination with recombinant vaccinia boost and PD-1 antibody","volume":"12","author":"Peng","year":"2021","journal-title":"MBio"},{"issue":"9","key":"10.1016\/j.pharmthera.2023.108399_bb0445","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1093\/infdis\/jir011","article-title":"Programmed death 1 and cytokine inducible SH2-containing protein dependent expansion of regulatory T cells upon stimulation with mycobacterium tuberculosis","volume":"203","author":"Periasamy","year":"2011","journal-title":"The Journal of Infectious Diseases"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108399_bb0450","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1038\/s41467-022-29930-0","article-title":"PD-L1 signaling selectively regulates T cell lymphatic transendothelial migration","volume":"13","author":"Piao","year":"2022","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2023.108399_bb0455","article-title":"Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: Living evidence syntheses and review","volume":"378","author":"Pillay","year":"2022","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"10","key":"10.1016\/j.pharmthera.2023.108399_bb0460","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/nm.2232","article-title":"Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF","volume":"16","author":"Quigley","year":"2010","journal-title":"Nature Medicine"},{"issue":"63","key":"10.1016\/j.pharmthera.2023.108399_bb0470","doi-asserted-by":"crossref","first-page":"eabh3034","DOI":"10.1126\/sciimmunol.abh3034","article-title":"PD-1 blockade and vaccination provide therapeutic benefit against SIV by inducing broad and functional CD8 + T cells in lymphoid tissue","volume":"6","author":"Rahman","year":"2021","journal-title":"Science Immunology"},{"issue":"4","key":"10.1016\/j.pharmthera.2023.108399_bb0475","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1001\/jamaoncol.2018.6437","article-title":"Prevalence of hepatitis B virus, hepatitis C virus, and HIV infection among patients with newly diagnosed cancer from academic and community oncology practices","volume":"5","author":"Ramsey","year":"2019","journal-title":"JAMA Oncology"},{"issue":"15_suppl","key":"10.1016\/j.pharmthera.2023.108399_bb0480","doi-asserted-by":"crossref","first-page":"e20657","DOI":"10.1200\/JCO.2019.37.15_suppl.e20657","article-title":"Immune related adverse events in NSCLC patients treated with immune checkpoint therapy who received the influenza vaccination versus no vaccination","volume":"37","author":"Reddy","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2023.108399_bb0485","doi-asserted-by":"crossref","DOI":"10.1158\/2326-6066.CIR-22-0541","article-title":"P. gingivalis infection upregulates PD-L1 expression on dendritic cells, suppresses CD8+ T cell responses, and aggravates oral cancer","author":"Ren","year":"2023","journal-title":"Cancer Immunology Research"},{"issue":"11","key":"10.1016\/j.pharmthera.2023.108399_bb0490","doi-asserted-by":"crossref","first-page":"S1125","DOI":"10.1016\/j.jtho.2019.09.019","article-title":"OA01.04 safety and efficacy of flu vaccination after treatment with immune checkpoint inhibitors: A retrospective review","volume":"14","author":"Roberts","year":"2019","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1016\/j.pharmthera.2023.108399_bb0495","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx091.032","article-title":"Immune response and adverse events to influenza vaccine in cancer patients undergoing PD-1 blockade","volume":"28","author":"Rothschild","year":"2017","journal-title":"Annals of Oncology"},{"issue":"18","key":"10.1016\/j.pharmthera.2023.108399_bb0500","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00827-19","article-title":"Blockade of PD-1 and LAG-3 immune checkpoints combined with vaccination restores the function of antiviral tissue-resident CD8 + T RM cells and reduces ocular herpes simplex infection and disease in HLA transgenic rabbits","volume":"93","author":"Roy","year":"2019","journal-title":"Journal of Virology"},{"issue":"10","key":"10.1016\/j.pharmthera.2023.108399_bb0505","doi-asserted-by":"crossref","first-page":"16824","DOI":"10.1002\/jcp.28358","article-title":"PD-1\/PD-L1 pathway: Basic biology and role in cancer immunotherapy","volume":"234","author":"Salmaninejad","year":"2019","journal-title":"Journal of Cellular Physiology"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108399_bb0510","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.immuni.2016.07.011","article-title":"Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis","volume":"45","author":"Schietinger","year":"2016","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108399_bb0515","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nature Reviews Immunology"},{"issue":"12","key":"10.1016\/j.pharmthera.2023.108399_bb0520","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20220745","article-title":"An engineered concealed IL-15-R elicits tumor-specific CD8+T cell responses through PD-1-cis delivery","volume":"219","author":"Shen","year":"2022","journal-title":"Journal of Experimental Medicine"},{"issue":"1\u20133","key":"10.1016\/j.pharmthera.2023.108399_bb0525","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.febslet.2004.07.083","article-title":"PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70\/CD3\u03b6 signalosome and downstream signaling to PKC\u03b8","volume":"574","author":"Sheppard","year":"2004","journal-title":"FEBS Letters"},{"key":"10.1016\/j.pharmthera.2023.108399_bb0530","article-title":"Brief research report: Anti-SARS-CoV-2 immunity in Long lasting responders to Cancer immunotherapy through mRNA-based COVID-19 vaccination","volume":"13","author":"Sister\u00e9-Or\u00f3","year":"2022","journal-title":"Frontiers in Immunology"},{"issue":"10","key":"10.1016\/j.pharmthera.2023.108399_bb0535","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1093\/infdis\/jix469","article-title":"Aspergillus fumigatus Cell Wall \u03b1-(1,3)-glucan stimulates regulatory T-cell polarization by inducing PD-L1 expression on human dendritic cells","volume":"216","author":"Stephen-Victor","year":"2017","journal-title":"The Journal of Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2023.108399_bb0540","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40364-020-00212-5","article-title":"Resistance to PD-1\/PD-L1 blockade cancer immunotherapy: Mechanisms, predictive factors, and future perspectives","volume":"8","author":"Sun","year":"2020","journal-title":"Biomarker Research"},{"issue":"11","key":"10.1016\/j.pharmthera.2023.108399_bb0545","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.3390\/cancers14112796","article-title":"SARS-CoV-2 neutralizing antibodies kinetics Postvaccination in cancer patients under treatment with immune checkpoint inhibition","volume":"14","author":"Terpos","year":"2022","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.pharmthera.2023.108399_bb0550","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.ccell.2021.06.002","article-title":"Seroconversion rates following COVID-19 vaccination among patients with cancer","volume":"39","author":"Thakkar","year":"2021","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.pharmthera.2023.108399_bb0555","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.3390\/vaccines10101673","article-title":"Programmed cell death protein 1 axis inhibition in viral infections: clinical data and therapeutic opportunities","volume":"10","author":"Tsiakos","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.pharmthera.2023.108399_bb0560","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coi.2019.02.007","article-title":"Tfh cell response in influenza vaccines in humans: What is visible and what is invisible","volume":"59","author":"Ueno","year":"2019","journal-title":"Current Opinion in Immunology"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108399_bb0565","doi-asserted-by":"crossref","first-page":"1886725","DOI":"10.1080\/2162402X.2021.1886725","article-title":"Improved survival without increased toxicity with influenza vaccination in cancer patients treated with checkpoint inhibitors","volume":"10","author":"Valachis","year":"2021","journal-title":"OncoImmunology"},{"issue":"4","key":"10.1016\/j.pharmthera.2023.108399_bb0570","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01240-w","article-title":"COVID-19 vaccination: The VOICE for patients with cancer","volume":"27","author":"van der Veldt","year":"2021","journal-title":"Nature Medicine"},{"issue":"15_suppl","key":"10.1016\/j.pharmthera.2023.108399_bb0575","doi-asserted-by":"crossref","first-page":"e18763","DOI":"10.1200\/JCO.2021.39.15_suppl.e18763","article-title":"Effect of influenza vaccination on immune-related adverse events in patients receiving single-agent immune checkpoint inhibitors for the treatment of cancer","volume":"39","author":"Vutukuri","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1016\/j.pharmthera.2023.108399_bb0580","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: From T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nature Reviews. Immunology"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108399_bb0585","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/cmi.12071","article-title":"Transcription factor complex AP-1 mediates inflammation initiated by Chlamydia pneumoniae infection","volume":"15","author":"Wang","year":"2013","journal-title":"Cellular Microbiology"},{"key":"10.1016\/j.pharmthera.2023.108399_bb0590","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3389\/fphar.2017.00730","article-title":"Immune-related adverse events associated with anti-PD-1\/PD-L1 treatment for malignancies: A meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108399_bb0595","article-title":"Cancer immunotherapies: From efficacy to resistance mechanisms - not only checkpoint matters","volume":"12","author":"Wang","year":"2021","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2023.108399_bb0600","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ejca.2018.09.012","article-title":"Influenza vaccination in patients with lung cancer receiving anti\u2013programmed death receptor 1 immunotherapy does not induce immune-related adverse events","volume":"104","author":"Wijn","year":"2018","journal-title":"European Journal of Cancer"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108399_bb0605","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1470-2045(21)00017-6","article-title":"SARS-CoV-2 vaccination and phase 1 cancer clinical trials","volume":"22","author":"Yap","year":"2021","journal-title":"The Lancet Oncology"},{"issue":"7","key":"10.1016\/j.pharmthera.2023.108399_bb0610","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002707","article-title":"Novel personalized cancer vaccine platform based on Bacillus Calmette-Gu\u00e8rin","volume":"9","author":"Yl\u00f6sm\u00e4ki","year":"2021","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"6","key":"10.1016\/j.pharmthera.2023.108399_bb0615","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1084\/jem.20112741","article-title":"Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2","volume":"209","author":"Yokosuka","year":"2012","journal-title":"The Journal of Experimental Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108399_bb0620","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1080\/22221751.2022.2093133","article-title":"Modulation of viral replication, apoptosis and antiviral response by induction and mutual regulation of EGR and AP-1 family genes during coronavirus infection","volume":"11","author":"Yuan","year":"2022","journal-title":"Emerging Microbes & Infections"},{"issue":"9","key":"10.1016\/j.pharmthera.2023.108399_bb0625","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108399_bb0630","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ccell.2021.12.014","article-title":"COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 omicron variant in patients with cancer","volume":"40","author":"Zeng","year":"2022","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.pharmthera.2023.108399_bb0635","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000515","article-title":"Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) expression in epithelial-originated Cancer: A Meta-analysis","volume":"94","author":"Zhang","year":"2015","journal-title":"Medicine"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725823000633?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725823000633?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:32:39Z","timestamp":1759012359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725823000633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":127,"alternative-id":["S0163725823000633"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108399","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The implication of anti-PD-1 therapy in cancer patients for the vaccination against viral and other infectious diseases","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108399","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108399"}}